Food and Drug Administration for perifosine, Aeterna Zentaris’ novel, first-in-class potentially, oral Akt inhibitor, for the treatment of neuroblastoma. Neuroblastoma is certainly a cancer of the nervous system affecting mostly children and infants that there are no FDA accepted therapies. Keryx is certainly Aeterna Zentaris’ partner and licensee for perifosine in the United States, Canada and Mexico. Related StoriesNew antenna-like device makes breast cancer medical procedures much easier for surgeonsViralytics enters into scientific trial collaboration contract with MSDSausages With Antioxidants From Berries To Prevent CancerJuergen Engel, Ph.D., President and CEO of Aeterna Zentaris stated, The orphan-medication designation in neuroblastoma is another essential milestone in the development of perifosine simply because a novel method of treating cancer patients, particularly in this region of unmet medical need.J-MAP measures the intensity, rate of recurrence, and quality of pain with response ranges from 1 to 7 where higher values indicate more pain. Suarez-Almazor. The team found significant differences in J-MAP pain decrease and satisfaction for those patients in the great expectations group compared with the neutral group. Suarez-Almazor. This scholarly study is published in Arthritis Treatment & Research. Suarez-Almazor, Carol Looney, Yanfang Liu, Vanessa Cox, Kenneth Pietz, Donald M. Marcus, and Richard l. Road, Jr. Arthritis Research and Care; Published Online: April 21, 2010 ; Print Issue Date: September 2010.. Adolescents tend to be powerful in influencing friends to start out smoking than to give up Adolescents tend to be powerful in influencing their friends to start out smoking than in helping them to quit, according to sociologists.